Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Multimodal LLM for Breast Cancer Radiotherapy Target Auto-Contouring and Planning

11. november 2026 oppdatert av: Xiaohui Zhao

Multimodal Data Fusion-Based Artificial Intelligence Large Language Model for Automated Target Volume Contouring and Intelligent Treatment Planning in Breast Cancer Radiotherapy: A Multicenter Ambidirectional Cohort Study

Breast cancer remains the most prevalent malignancy among women worldwide, with a continuously increasing incidence. As a crucial component of comprehensive cancer treatment, radiotherapy plays a key role in reducing local recurrence rates and improving overall survival outcomes. However, traditional radiotherapy target volume contouring and treatment planning design rely heavily on clinician expertise, presenting challenges such as prolonged processing time, significant inter-observer variability, and high subjectivity in dose optimization. Although artificial intelligence has made substantial progress in automated contouring and planning, conventional single-modal models still face major limitations. These models struggle to effectively integrate clinical text, tumor biological characteristics, and dose distribution factors, resulting in restricted generalizability. Therefore, developing an intelligent radiotherapy assistance system capable of multimodal data fusion is of high clinical significance to enhance precision and efficiency in breast cancer radiotherapy.

This study aims to develop an innovative breast cancer radiotherapy assistance system based on a multimodal large language model. By integrating multimodal imaging data (including CT, MRI, and ultrasound), pathology reports, and structured electronic health record text, the system realizes end-to-end intelligence from target volume contouring to treatment plan generation. Employing a multicenter, ambidirectional cohort design, the study collects comprehensive clinical data from breast cancer patients who have undergone breast-conserving surgery or mastectomy. Technologically, the system innovatively combines the natural language processing capabilities of large language models with the image analysis strengths of deep learning, utilizing attention mechanisms to achieve deep fusion and interactive comprehension of heterogeneous medical data. Notably, the system breaks through traditional radiotherapy planning workflows by jointly optimizing target contouring and dose planning as a unified pipeline, applying reinforcement learning algorithms to dynamically balance target volume coverage with organ-at-risk protection. The outcomes of this study will provide an important paradigm for the clinical application of AI in radiation oncology and advance the field of precision radiotherapy.

Studieoversikt

Studietype

Observasjonsmessig

Registrering (Antatt)

51000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Guangdong
      • Guangzhou, Guangdong, Kina, 510120
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xiaohui Zhao, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

The study population includes patients with breast cancer from multiple medical centers. The retrospective cohort comprises patients treated at Sun Yat-sen Memorial Hospital (n=35,000) and external collaborating centers (Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Zhoukou Central Hospital, and Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, n=15,000) between January 1, 2002, and October 31, 2025. The prospective test cohort comprises patients prospectively enrolled at Sun Yat-sen Memorial Hospital starting from January 1, 2026 (n=1,000).

Beskrivelse

Inclusion Criteria:

  • Patients with pathologically confirmed breast malignant tumors who require postoperative adjuvant radiotherapy following radical surgery.
  • Availability of complete pathology reports.
  • Availability of complete imaging examinations and reports (such as CT, MRI, ultrasound, X-ray).
  • Availability of standardized clinical medical records.

Exclusion Criteria:

  • Patients with missing data.
  • Patients with primary multiple cancers.
  • Patients receiving salvage or palliative radiotherapy.
  • Patients receiving accelerated partial breast irradiation (APBI).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: OTHER

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Retrospective Training and Internal Validation Cohort

Retrospective collection of clinical data, multimodal images (MRI, CT, ultrasound, X-ray), pathology reports, and radiotherapy plans from patients with breast cancer treated at Sun Yat-sen Memorial Hospital between January 1, 2002, and October 31, 2025. This cohort (n=35,000) is used for model training and internal validation of the multimodal LLM-assisted automated contouring and radiotherapy planning system.

The study evaluates an innovative multimodal large language model (LLM) system designed for automated target volume delineation and intelligent treatment planning in post-operative breast cancer radiotherapy. The system integrates clinical text, multimodal imaging (CT, MRI, ultrasound, X-ray), and pathology data to joint-optimize contouring and dose planning without direct patient intervention.

Retrospective External Validation Cohort

Retrospective collection of data from external collaborative centers (Sun Yat-sen Memorial Hospital Shenzhen Hospital, Zhoukou Central Hospital, and Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) between January 1, 2002, and October 31, 2025 (total n=15,000). This cohort is used to evaluate the external generalizability and robustness of the multimodal AI model.

The study evaluates an innovative multimodal large language model (LLM) system designed for automated target volume delineation and intelligent treatment planning in post-operative breast cancer radiotherapy. The system integrates clinical text, multimodal imaging (CT, MRI, ultrasound, X-ray), and pathology data to joint-optimize contouring and dose planning without direct patient intervention.

Prospective Test Cohort

Prospective collection of data from patients with breast cancer treated at Sun Yat-sen Memorial Hospital starting from January 1, 2026 (n=1,000). This cohort undergoes double-blind evaluation to prospectively test the performance of the multimodal LLM-driven target volume auto-segmentation and intelligent radiotherapy planning system in clinical practice.

The study evaluates an innovative multimodal large language model (LLM) system designed for automated target volume delineation and intelligent treatment planning in post-operative breast cancer radiotherapy. The system integrates clinical text, multimodal imaging (CT, MRI, ultrasound, X-ray), and pathology data to joint-optimize contouring and dose planning without direct patient intervention.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Dice Similarity Coefficient (DSC) of Target Volume Auto-Segmentation
Tidsramme: Baseline

Evaluation of the Dice Similarity Coefficient (DSC) between AI-generated automatic breast cancer target volume contours and expert manual contours.

Baseline

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
95% Hausdorff Distance (95HD) of Target Volume Auto-Segmentation
Tidsramme: Baseline

Evaluation of the 95% Hausdorff Distance (95HD) between AI-generated automatic breast cancer target volume contours and expert manual contours.

Baseline
Intersection over Union (IoU) of Target Volume Auto-Segmentation
Tidsramme: Baseline

Evaluation of the Intersection over Union (IoU) between AI-generated automatic breast cancer target volume contours and expert manual contours.

Baseline
Clinical Evaluation Score of Target Volume Auto-Segmentation
Tidsramme: Baseline

Blinded evaluation by radiation oncology experts using the Investigator-Developed Cancer Target Volume Contouring Performance Evaluation Scale, a structured 5-point clinical evaluation scale. The scale assesses five dimensions: laterality accuracy (0 to 1 point), radiotherapy type suitability (0 to 1 point), target volume definition (0 to 1.5 points), coverage (0 to 1 point), and structural integrity (0 to 0.5 points). The total score ranges from a minimum of 0 to a maximum of 5, where higher scores indicate better target volume contouring quality and clinical acceptability.

Baseline

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Xiaohui Zhao, MD, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

9. november 2026

Primær fullføring (Antatt)

1. desember 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

2. november 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • SYSKY-2026-014-01

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere